ALZN - Alzamend Neuro, Inc.
1.98
0.030 1.515%
Share volume: 29,977
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$1.95
0.03
0.02%
View ratios
| Fiscal Date | 01-31-2024 | 04-30-2024 | 07-31-2024 | 10-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2024 | Q4 2024 | Q1 2024 | Q2 2024 | |
| Report Date | 03-25-2024 | 07-22-2025 | 09-11-2024 | 12-11-2024 | |
| Assets | |||||
| Total Assets | 782.636 K | 631.588 K | 1.670 M | 5.008 M | |
| Current Assets | 593.605 K | 455.242 K | 1.416 M | 4.767 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 282.867 K | 376.048 K | 1.194 M | 4.093 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 189.031 K | 176.346 K | 253.661 K | 240.976 K | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||
| Total Liabilities and shareholders’ equity | 782.636 K | 631.588 K | 1.670 M | 5.008 M | |
| Total liabilities | 4.569 M | 3.226 M | 2.882 M | 1.255 M | |
| Total current liabilities | 3.826 M | 3.226 M | 2.882 M | 1.255 M | |
| Accounts Payable | 3.826 M | 2.925 M | 2.882 M | 1.255 M | |
| Other liabilities | 742.263 K | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 742.263 K | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -4.264 M | -2.594 M | -1.212 M | 3.753 M | |
| Common stock | 48.975 M | 51.426 M | 53.783 M | 60.163 M | |
| Retained earnings | -53.169 M | -54.020 M | -54.995 M | -56.410 M |